Ineos USA LLC v. Berry Plastics Corporation
783 F.3d 865
Fed. Cir.2015Background
- Ineos USA LLC accused Berry Plastics of infringing the ’863 patent, which covers polyethylene-based bottle-cap compositions with specific lubricant/additive ranges.
- The district court granted summary judgment that the ’863 patent is invalid as anticipated under 35 U.S.C. § 102 (2006).
- Limitations of claim 1 include: at least 94.5% polyethylene (>940 kg/m3), 0.05–0.5% of a primary lubricant, and 0–5% of one or more additives such as antioxidants or UV stabilizers.
- The prior art ’846 patent discloses 94.5% polyethylene and a primary lubricant within 0.1–0.4 parts by weight, with optional subsidiary lubricant and additives.
- The district court concluded that the ’846 patent discloses limitation 2 (primary lubricant) and limitation 3 (subsidiary lubricant) and that limitation 4 (additives) is optional.
- Ineos appealed arguing the ’846 patent does not disclose a specific point within the claimed ranges and that criticality of ranges should preclude anticipation under OSRAM/
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Was claim 1 anticipated by the ’846 patent? | Ineos argues ’846 discloses ranges, not specific points, and the overlap is insufficient for anticipation. | Berry contends ’846 discloses specific points (0.1, 0.2, 0.4) within the range and thus anticipates. | Yes; limitation 2 anticipated; ’846 discloses points within the range. |
| Does the prior art disclose a critical range rendering OSRAM/criticality moot? | Ineos argues the claimed range is critical, so anticipation should fail. | Berry contends no genuine fact issue on criticality; prior art points within range anticipate. | No error; lack of genuine dispute on criticality; anticipation stands. |
| Is limitation 3 (subsidiary lubricant 0–0.15%) met by the ’846 patent? | Ineos contends criticality of both limitation 2 and 3 should be considered. | Berry argues ’846 discloses a single lubricant with possible 0% subsidiary lubricant. | Yes; limitation 3 is met; subsidiary lubricant can be 0%. |
| Does the ’846 patent anticipate claim 3 (behenamide as a species)? | Ineos asserts behenamide is not explicitly disclosed in ’846. | Berry contends the genus of saturated fatty acid amides in ’846 includes behenamide; no dispute of material fact. | Yes; claim 3 anticipated by genus disclosure of saturated fatty acid amides including behenamide. |
Key Cases Cited
- Titanium Metals Corp. v. Banner, 778 F.2d 775 (Fed. Cir. 1985) (anticipation when prior art discloses a point within a claimed range)
- Atofina v. Great Lakes Chemical Corp., 441 F.3d 991 (Fed. Cir. 2006) (range disclosures and endpoints; criticality affects anticipation)
- OSRAM Sylvania, Inc. v. American Induction Technologies, Inc., 701 F.3d 698 (Fed. Cir. 2012) (summary judgment reversal where criticality of range was supported by evidence)
- ClearValue, Inc. v. Pearl River Polymers, Inc., 668 F.3d 1340 (Fed. Cir. 2012) (criticality absence negates anticipation when prior art range is broad)
- In re Petering, 301 F.2d 676 (C.C.P.A. 1962) (genus-to-species disclosure can anticipate)
- American Calcar, Inc. v. American Honda Motor Corp., 651 F.3d 1318 (Fed. Cir. 2011) (standard for enabling disclosure and practice of invention)